|
|
Article: Calando To Use Alnylam's RNAi Portfolio For Cancer.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Calando Pharmaceuticals Inc. licensed access to intellectual property from Alnylam Pharmaceuticals Inc. to develop an RNAi-based drug for cancer.
Specific terms of the deal were not disclosed, but Calando agreed to pay Alnylam up-front, annual and milestone payments, as well as royalties on any products covered by the agreement. Calando also has the option to add a license for a second target.
Founded as a majority-held subsidiary of Arrowhead Research Corp. in February 2005, Calando focuses on developing RNAi-based therapeutics that can be delivered through its systemic, nonviral delivery system. To date, the company has raised ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|